Effects of anti-allergic ophthalmic solutions on chemical mediators in tear fluid and on expression of chemical mediator receptors on conjunctival epithelial cells in patients with allergic conjunctivitis for pre-seasonal therapy
Not Applicable
- Conditions
- Seasonal allergic conjunctivitis
- Registration Number
- JPRN-UMIN000030789
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Brief Summary
69 cases (Epinastine Intervention Group; 35 cases, Switch from Artificial Tears to Epinastine Intervention Group; 34 cases) were enrolled. As for both groups, expression levels of chemical mediator receptor mRNA on conjunctival epithelial cells were significantly increased at week 12 from the baseline (week 0). As for both groups, levels of chemical mediation in tears were not changed significantly. Through the study period, there were no side effects for both groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 69
Inclusion Criteria
Not provided
Exclusion Criteria
Patient under immunotherapy (including hyposensitization therapy and allassotherapy) Has history of allergy to the ingredients of the study drug and clinical reagents Patient who the investigator considers ineligible for enrolment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in values of the following After 4weeks and 12weeks therapy -Expression levels of chemical mediator receptor mRNA on conjunctival epithelial cells -Levels of chemical mediator in tears
- Secondary Outcome Measures
Name Time Method Change in values of the following After 4weeks and 12weeks therapy -Subjective symptom scores -Objective finding scores Adverse event